Alumis Inc. announced the successful pricing of an upsized underwritten offering of 17.65 million shares of its common stock at $17.00 per share, resulting in gross proceeds of roughly $300 million before underwriting discounts, commissions and expenses. The offering, led by Morgan Stanley, Leerink Partners, Cantor Fitzgerald and Wells Fargo Securities as joint book-running managers, is expected to close on January 9, 2026, subject to customary conditions. Underwriters have also been granted a 30-day option to purchase up to an additional 2.6475 million shares at the public offering price, less discounts.

Alumis reported that its lead TYK2 inhibitor, envudeucitinib (envu), met all primary and key secondary endpoints in two pivotal Phase III trials for moderate-to-severe plaque psoriasis. Data showed approximately two-thirds of patients achieved at least 90% skin clearance (PASI 90) and over 40% reached complete clearance by Week 24. The safety profile was consistent with previous studies, with low discontinuation rates and no new safety signals observed.

With the new capital infusion, Alumis plans to accelerate its regulatory submission timeline for envudeucitinib, targeting a New Drug Application filing in mid-2026. The company also intends to advance A-005 into Phase I for neuroinflammatory indications and progress its subcutaneous anti-IGF-1R candidate, lonigutamab, into clinical development for thyroid eye disease. Management highlighted the importance of the proprietary data analytics platform in driving patient selection strategies and optimizing trial design across its immune-mediated disease pipeline.